Salman Yousuf, DO
Ophthalmology · Washington, DCNPI 1669600649
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,700 of the $5,435 with a category attached, or 86.5%. Regeneron accounts for 88.9% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $5,022 and has fallen 96.2% since, to $189 in 2025.
Across 15 payments — averaging $362.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$5K
- Glaukos Corporation$347
- Alcon$111
- AbbVie$65
- Novartis$29
- Regeneron Healthcare Solutions, Inc.$20
- plus $31 from 2 others
What the payments were for
- Consulting fees$4,70086%
- Food & beverage$73514%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 3 | $4,831 |
| Glaukos Corporation | 4 | $347 |
| Alcon | 1 | $111 |
| AbbVie(2 entities) | 3 | $65 |
| Novartis | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Amgen | 1 | $17 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$4,831
- iAccess Precision Blade$158
- iDoseTR$136
- Luxor$111
- Constellation$111
- LenSx$111
How this compares
$5,435 in reported general payments places this provider in the 80th percentile of 74 ophthalmology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 26 | $1,137 |
| Latanoprost | 98 | $421 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 17 | $200 |
| Timolol Maleate | 11 | $97 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Washington
- Wiley ChambersWashington$618K
- Keesha Williams ElliottWashington$167K
- Samuel StopakWashington$33K
- Jonca BullWashington$30K
- Leslie JonesWashington$22K
- Alexander HacopianWashington$13K
- Mehdi Tavakoli DastjerdiWashington$12K
- Andrew HammerWashington$11K
- Thandeka MyeniWashington$10K
- Dipak PanigrahiWashington$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.